Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Colorectal Neoplasms 42Colonic Neoplasms 14Rectal Neoplasms 13Neoplasms 12Neoplasm Metastasis 12Head and Neck Neoplasms 6Esophageal Neoplasms 6Squamous Cell Carcinoma of Head and Neck 4Pancreatic Neoplasms 4Carcinoma, Squamous Cell 4Breast Neoplasms 4Recurrence 3Lung Neoplasms 3Carcinoma, Non-Small-Cell Lung 3Adenocarcinoma Of Esophagus 3Triple Negative Breast Neoplasms 2Gastrointestinal Neoplasms 2Cholangiocarcinoma 2Carcinoma 2Biliary Tract Neoplasms 2Urinary Bladder Neoplasms 1Solid Tumors 1Ovarian Neoplasms 1Inflammatory Breast Neoplasms 1Gliosarcoma 1Glioma 1Glioblastoma 1Gallbladder Neoplasms 1Fallopian Tube Neoplasms 1Exanthema 1

Interventions

Panitumumab 1Gemcitabine 1Cystectomy 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Cone Dystrophy 3 × Panitumumab × Clear all
NCT01916109 2016-02-12

Study of Gemcitabine, Carboplatin, and Panitumumab (GCaP) as Neoadjuvant Chemotherapy in Patients With Muscle-Invasive Bladder Cancer

Memorial Sloan Kettering Cancer Center

Phase 2 Terminated
4 enrolled 6 charts
Genitourinary

Cone Dystrophy 3, Urinary Bladder Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡